Therapy Areas: Oncology
Sengenics Partners with the Foundation for the National Institutes of Health Biomarkers Consortium
15 July 2019 - - Singapore-based functional proteomics company Sengenics has joined the Foundation for the National Institutes of Health Biomarkers Consortium, the company said.
As a member of the consortium, Sengenics aims to further accelerate the identification and commercialisation of autoantibody biomarkers for early diagnosis of cancer and autoimmune diseases as well as development of new companion diagnostics tests.
The FNIH Biomarkers Consortium was co-founded by the US National Institutes of Health, the US Food and Drug Administration, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Centers for Medicare and Medicaid Services and BIO.
It counts amongst its list of contributing members, major pharmaceutical companies such as Novartis, GSK and Merck; as well as not-for-profit organisations such as the Alzheimer's Drug Discovery Foundation and the American Heart Association.
Sengenics will work with the FNIH Biomarkers Consortium to provide expertise about the discovery of autoantibodies for diagnostics, companion diagnostics and therapeutics applications, particularly through its proprietary KREX technology.
As KREX-based protein arrays use antigens that are correctly folded and functional, autoantibodies are detected with very high specificity and sensitivity.
The technology has already been applied to discover autoantibody biomarkers with both diagnostic and protective potential for cancers, autoimmune diseases and neurodegenerative disorders.
KREX protein arrays have also been used for stratification of patients into responders, non-responders and those exhibiting immune-related adverse events (irAEs). This has been achieved with very high positive predictive values and negative predictive values for patients on autoimmune or immune checkpoint inhibitor drugs.
Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins.
KREX was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge.
The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases.
Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events (irAEs).
Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world's premier medical research agency.
The foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c) (3) charitable organisation.